CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.116495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Jonathan Boucher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada. Electronic address: jonathan.boucher@umontreal.…. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Melanoma, Core Binding Factor beta Subunit, Cyclin-Dependent Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Santé, Cancer Research Society.
Abstract (Originalsprache)
Cutaneous melanoma is the deadliest form of skin cancer, frequently driven by hyperactivation of the RAS/mitogen-activated protein kinase (MAPK) pathway. Cyclin-dependent kinase 12 (CDK12), a downstream effector of MAPK signaling, has emerged as a therapeutic target due to its essential role in transcriptional regulation and DNA damage repair. To identify vulnerabilities associated with CDK12 inhibition, we performed a genome-wide CRISPR-Cas9 screen and identified the Runt-related transcription factor RUNX1 and its cofactor CBFβ as synthetic lethal partners of CDK12. RUNX1 inhibition enhanced melanoma sensitivity to CDK12 inhibitors in a p53-independent manner, resulting in DNA damage accumulation and impaired repair capacity. Combined inhibition of CDK12 and RUNX1 suppressed melanoma growth in vivo. These findings identify RUNX1/CBFβ as a compensatory mechanism in CDK12-inhibited melanoma and define a synthetic lethal interaction with translational potential for combinatorial therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada. Electronic address: jonathan.boucher@umontreal.ca.
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada.
- Donnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Donnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Department of Bi…
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada; Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada. Electron…
Förderung
- CIHR
- Santé
- Cancer Research Society
Zitieren
APA
Boucher, J., Houles, T., Berliocchi, E., Lavoie, G., MacLeod, G., Saba-El-Leil, M. K., Angers, S., Meloche, S., & Roux, P. P. (2025). CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116495
Vancouver
Boucher J, Houles T, Berliocchi E, Lavoie G, MacLeod G, Saba-El-Leil MK, et al. CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116495
BibTeX
@article{Boucher2025,
author = {Boucher, Jonathan and Houles, Thibault and Berliocchi, Elsa and Lavoie, Geneviève and MacLeod, Graham and Saba-El-Leil, Marc K and Angers, Stephane and Meloche, Sylvain and Roux, Philippe P},
title = {CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.116495}
}
EUVIMED